Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
3 h+ |0 A% g7 MNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 * k0 q" w5 ~" g0 f0 i2 b
+ Author Affiliations
" P; J) @) n- ]3 m" A- g2 d x! ]
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan . r- m3 |! u8 Z( m2 Y
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
3 L1 b; I/ D2 ]& V0 P |, j8 u, D3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan # c9 N+ n2 t @* R- N& O
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan - v: g j! |4 L/ H" W
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan ' Y8 N) j( @9 o6 @
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
6 T9 I+ t1 N* i1 V7Kinki University School of Medicine, Osaka 589-8511, Japan
, j- ]( @% h' g& R( V8Izumi Municipal Hospital, Osaka 594-0071, Japan 5 T$ ] X& a# N
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
' m1 F( F3 |- w$ SCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
3 C# A- k, k! T4 X) Q0 i* j! eAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
+ T3 y- ?+ w( g6 u) h
# s2 i0 \- y. r0 {3 ? |